ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
Part of Cancer, Skin clinical trials.
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old with hormone receptor-positive (HR+) and HER2-negative breast cancer.
- You must have a tumor that is at least stage T1c-2N0M0 with high-risk features, or T3N0M0, or any tumor with positive lymph nodes.
- You need to have not received any prior treatment for this breast cancer (like chemotherapy, radiation, or hormone therapy).
- Your overall health should be good enough that you can do most daily activities (ECOG 0-1).
- You cannot have had another cancer in the last 5 years (except for some cured skin cancers or cervical carcinoma in situ).
- You must not have serious lung or heart problems, active infections, or certain viral infections like HIV or untreated hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of two targeted drugs (dalpiciclib and an HDAC inhibitor) for people with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 inhibitor treatment. The goal is to see if this new combination can help control the cancer.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.